Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6485316 | Biomaterials | 2016 | 14 Pages |
Abstract
Regional overexpression of the multidrug transporter P-glycoprotein (P-gp) in epileptic brain tissues may lower antiepileptic drugs concentrations at the target site and contribute to pharmacoresistance in refractory epilepsy. However, few techniques are available to quantitate the level of P-gp expression noninvasively in vivo. In this study, we developed a nanoagent by conjugating superparamagnetic iron oxide nanoparticles with a near infrared probe and the targeting element Pepstatin A, a peptide with specific affinity for P-gp. In a rat model of epilepsy, the nanoagent was readily and selectively accumulated within epileptogenic cerebral regions, which were detectable by both magnetic resonance imaging and optical imaging modalities. This P-gp-targeted nanoagent could be used not only in the molecular imaging of P-gp expression changes in seizure-induced regional, understanding the mechanisms of P-gp disorders, and the prediction of refractory epilepsy, but also in targeted therapies with P-gp modulators.
Related Topics
Physical Sciences and Engineering
Chemical Engineering
Bioengineering
Authors
Xiangrong Yu, Jianhong Wang, Jiansheng Liu, Shun Shen, Zhonglian Cao, Jiawei Pan, Shuyi Zhou, Zhiqing Pang, Daoying Geng, Jun Zhang,